Episode
Selpercatinib Halts Lung Cancer Recurrence
- Published
- May 31, 2026
- Duration seconds
- 89
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/los-angeles-news-today-2-min-news-the-daily-news-now-7458113/episodes/selpercatinib-halts-lung-cancer-recurrence/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/los-angeles-news-today-2-min-news-the-daily-news-now-7458113/selpercatinib-halts-lung-cancer-recurrence.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
A groundbreaking UCLA-led study reveals selpercatinib, a targeted drug for rare early-stage lung cancer, slashes recurrence risk by 83%—with 92% of patients staying cancer-free after two years versus just 61% on placebo. This game-changing therapy, tested in a major international trial, offers new hope for patients post-surgery and marks a major leap in personalized cancer treatment. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/9d6c42db79d71d72